SELLAS Life Sciences (SLS) Other financing activities (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Other financing activities of $66000.0 for Q1 2026, up 37.5% year-over-year from $48000.0 in Q1 2025, and up 100.3% quarter-over-quarter from -$21.9 million in Q4 2025.
SELLAS Life Sciences (SLS) Other financing activities (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Other financing activities for 13 consecutive years, with $66000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 37.5% year-over-year to $66000.0; the TTM figure through Mar 2026 stood at $130000.0 (down 76.74% YoY), while the FY2025 annual figure was $112000.0, down 80.0% from the prior year.
- Other financing activities advanced to $66000.0 in Q1 2026 per SLS's latest filing, from -$21.9 million in the prior quarter.
- Across five years, Other financing activities topped out at $22.0 million in Q3 2025 and bottomed at -$21.9 million in Q4 2025.
- Historically, Other financing activities has averaged $74250.0 across 5 years, with a median of $47500.0 in 2022.
- On a YoY basis, Other financing activities climbed as much as 4226.57% in 2025 and fell as far as 2191600.0% in 2025.
- SELLAS Life Sciences' Other financing activities stood at $38000.0 in 2022, then sank by 63.16% to $14000.0 in 2023, then sank by 92.86% to $1000.0 in 2024, then sank by 2191600.0% to -$21.9 million in 2025, then jumped by 100.3% to $66000.0 in 2026.
- Business Quant data shows SLS's Other financing activities at $66000.0 in Q1 2026, -$21.9 million in Q4 2025, and $22.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Jun 30, 2026 | 100,000.00 |
| Mar 31, 2026 | 66,000.00 |
| Mar 31, 2026 | 66,000.00 |
| Dec 31, 2025 | -21.92 Mn |
| Dec 31, 2025 | -21.92 Mn |
| Sep 30, 2025 | 21.98 Mn |
| Sep 30, 2025 | 21.98 Mn |
| Mar 31, 2025 | 48,000.00 |
| Mar 31, 2025 | 48,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 508,000.00 |
| Sep 30, 2024 | 508,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2023 | 14,000.00 |